Your browser doesn't support javascript.
loading
Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.
Kesavardhana, Sannula; Das, Raksha; Citron, Michael; Datta, Rohini; Ecto, Linda; Srilatha, Nonavinakere Seetharam; DiStefano, Daniel; Swoyer, Ryan; Joyce, Joseph G; Dutta, Somnath; LaBranche, Celia C; Montefiori, David C; Flynn, Jessica A; Varadarajan, Raghavan.
Afiliação
  • Kesavardhana S; From the Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012, India.
  • Das R; From the Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012, India.
  • Citron M; Merck & Company, Inc., West Point, Pennsylvania 19486, and.
  • Datta R; From the Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012, India.
  • Ecto L; Merck & Company, Inc., West Point, Pennsylvania 19486, and.
  • Srilatha NS; From the Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012, India.
  • DiStefano D; Merck & Company, Inc., West Point, Pennsylvania 19486, and.
  • Swoyer R; Merck & Company, Inc., West Point, Pennsylvania 19486, and.
  • Joyce JG; Merck & Company, Inc., West Point, Pennsylvania 19486, and.
  • Dutta S; From the Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012, India.
  • LaBranche CC; the Department of Surgery, Duke University, Durham, North Carolina 27705.
  • Montefiori DC; the Department of Surgery, Duke University, Durham, North Carolina 27705.
  • Flynn JA; Merck & Company, Inc., West Point, Pennsylvania 19486, and jessica_flynn@merck.com.
  • Varadarajan R; From the Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012, India, varadar@mbu.iisc.ernet.in.
J Biol Chem ; 292(1): 278-291, 2017 Jan 06.
Article em En | MEDLINE | ID: mdl-27879316
ABSTRACT
A major goal for HIV-1 vaccine development is an ability to elicit strong and durable broadly neutralizing antibody (bNAb) responses. The trimeric envelope glycoprotein (Env) spikes on HIV-1 are known to contain multiple epitopes that are susceptible to bNAbs isolated from infected individuals. Nonetheless, all trimeric and monomeric Env immunogens designed to date have failed to elicit such antibodies. We report the structure-guided design of HIV-1 cyclically permuted gp120 that forms homogeneous, stable trimers, and displays enhanced binding to multiple bNAbs, including VRC01, VRC03, VRC-PG04, PGT128, and the quaternary epitope-specific bNAbs PGT145 and PGDM1400. Constructs that were cyclically permuted in the V1 loop region and contained an N-terminal trimerization domain to stabilize V1V2-mediated quaternary interactions, showed the highest homogeneity and the best antigenic characteristics. In guinea pigs, a DNA prime-protein boost regimen with these new gp120 trimer immunogens elicited potent neutralizing antibody responses against highly sensitive Tier 1A isolates and weaker neutralizing antibody responses with an average titer of about 115 against a panel of heterologous Tier 2 isolates. A modest fraction of the Tier 2 virus neutralizing activity appeared to target the CD4 binding site on gp120. These results suggest that cyclically permuted HIV-1 gp120 trimers represent a viable platform in which further modifications may be made to eventually achieve protective bNAb responses.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Anticorpos Anti-HIV / Proteína gp120 do Envelope de HIV / Infecções por HIV / HIV-1 / Anticorpos Neutralizantes Idioma: En Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Anticorpos Anti-HIV / Proteína gp120 do Envelope de HIV / Infecções por HIV / HIV-1 / Anticorpos Neutralizantes Idioma: En Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Índia